$24.730
-0.267 (-1.08%)收盤時
PTHS 資訊
PTHS 事件
Pelthos Reports Q1 Revenue of $10.91M, Exceeding Expectations
Reports Q1 revenue $10.91M, consensus $10.44M. Scott Plesha, CEO of Pelthos, stated, "In the first quarter of 2026, we continued to build momentum for ZELSUVMI, driven by the expansion of our sales force and focused commercial execution. The increase in dispensed units positions us well for continued growth in the second quarter and beyond. Looking ahead, we anticipate ongoing growth for ZELSUVMI, with dispensed units in April reaching 3,776 and total units dispensed since launch surpassing a significant milestone of 20,000. We believe our continued commercial performance, paired with the Horizon facility we entered into earlier this year, will provide us the capital and flexibility needed to advance our business plan, including the planned commercialization of XEPI and XEGLYZE in early 2027 and mid-2027, respectively."
Pelthos Therapeutics Appoints John Gay as CFO
Pelthos Therapeutics announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II, who served as Pelthos' CFO since July 2025. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has more than 25 years of public company finance and accounting experience.
Pelthos Therapeutics Begins CT2000 Clinical Trial
Pelthos Therapeutics announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos' subsidiary Channel Pharmaceutical Corporation owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary.
Pelthos Therapeutics Inc Trading Halted Due to Volatility Trading Pause
Pelthos Therapeutics Inc trading halted, volatility trading pause
Zelsuvmi Q4 Revenue Reaches $9.1M
Reports Q4 Zelsuvmi revenue $9.1M vs. $7.1M vs. last year. CEO Scott Plesha commented, "We are delighted with the growth of Zelsuvmi in our second quarter of commercialization despite the seasonal reduction of patients seeking MC treatment during Q4. The launch metrics, including prescriptions, revenue growth, gross to net discounts and other financial results, have exceeded our expectations. We anticipate strong continued growth for Zelsuvmi in 2026 and with the capital raised with the issuance of the convertibles notes in November 2025 and the term debt issued in January 2026, we believe that our cash balance provides the runway to execute on our business plan. In addition, the recent acquisition of Xepi and Xeglyze have added two highly complementary products to our portfolio. FDA-approved Xepi and Xeglyze each treat infectious skin conditions primarily impacting children, which aligns with the same target market as Zelsuvmi . This presents our sales reps and Pelthos with a synergistic opportunity to increase revenue by leveraging our current commercial relationships and infrastructure with de minimis additional SG&A. We believe we are well-positioned to capitalize on the large addressable markets and unmet needs presented by these three products and have the commercial infrastructure and experience to continue to grow Zelsuvmi and launch and grow Xepi and Xeglyze."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。